Weekly oral prednisolone improves survival and strength in malemdx mice

Autor: Elizabeth M. Streif, Paul T. Golumbek, Anne M. Connolly, Richard M. Keeling
Rok vydání: 2006
Předmět:
Male
musculoskeletal diseases
congenital
hereditary
and neonatal diseases and abnormalities
mdx mouse
Weakness
medicine.medical_specialty
Physiology
medicine.drug_class
Prednisolone
animal diseases
Duchenne muscular dystrophy
Anti-Inflammatory Agents
Administration
Oral
Drug Administration Schedule
Dystrophin
Mice
Cellular and Molecular Neuroscience
Grip strength
Physiology (medical)
Internal medicine
medicine
Animals
Muscle Strength
Muscular dystrophy
Muscle
Skeletal
Muscle Weakness
business.industry
Body Weight
Age Factors
musculoskeletal system
medicine.disease
Mice
Inbred C57BL
Muscular Dystrophy
Duchenne
Survival Rate
Disease Models
Animal
Treatment Outcome
Endocrinology
medicine.anatomical_structure
Muscle Fatigue
Mice
Inbred mdx
Corticosteroid
Neurology (clinical)
medicine.symptom
Forelimb
business
Muscle Contraction
medicine.drug
Zdroj: Muscle & Nerve. 35:43-48
ISSN: 1097-4598
0148-639X
Popis: Although corticosteroids alleviate weakness in mdx mice, no long-term treatment has determined whether this benefit is maintained. We studied mdx mice forelimb grip strength and fatigue from 3 through 84 weeks and followed survival through 104 weeks. The mdx mice were given twice weekly oral prednisolone (5 mg/kg) beginning at 3 or 4 weeks. Treated mdx mice survived longer than untreated mice. Between 3 and 10 weeks, treated and untreated mdx mice had similar strength. Between 10 and 24 weeks, strength and strength per gram body weight declined more slowly in treated than untreated mdx mice. Between 24 and 84 weeks, treated and untreated mdx mice declined in strength at the same rate, although treated mice remained stronger. Forelimb grip fatigue was present in untreated mdx mice at all time-points compared to wild-type and was not changed significantly by treatment. We have demonstrated long-term benefit of oral prednisolone in the mdx mouse model of Duchenne muscular dystrophy (DMD). As corticosteroids remain the most validated long-term treatment of DMD, this work may allow for better prediction of synergistic treatments likely to translate to effective improvement for boys with this progressive muscular dystrophy.
Databáze: OpenAIRE
Externí odkaz: